Best of ASCO - 2014 Annual Meeting

 

Welcome

Uterine Cancer

Gynecologic Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A comparison of adjuvant therapy approaches for patients with early-stage uterine serous carcinoma.

Katherine Kurnit

5517

A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.

Vicky Makker

TPS5607

A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.

Maria M Rubinstein

5582

A phase II, open labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer: KCOGG1303 study.

Kensuke Hori

5584

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

Matthew A. Powell

5500

Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).

Yoland Catherine Antill

5501

Association betweenBRCA1 and BRCA2 mutations and prognosis in women with endometrial carcinoma.

Aifen Wang

e17115

Association of total hysterectomy with survival among newly diagnosed uterine cancer patients with distant organ metastasis.

Yuefeng Wang

5583

AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

Nicoletta Colombo

TPS5608

Clinicopathological significance and prognostic value of intratumoral and peritumoral lymphocytes in endometrial cancer patients.

Martin Ore-Arce

e17116

Comparison of preoperative serum VEGF in leiomyosarcoma and uterus myomatosus patients: A proof of concept study.

Amelie De Gregorio

e17117

Differential vaginal wall dosing in high-dose rate brachytherapy for endometrial cancer: The potential for superior coverage of at-risk areas while preserving organs at risk—An analysis of simulated data.

Dhiraj Sinha

e17121

Does mismatch repair (MMR) deficiency have prognostic significance in low-risk endometrioid endometrial cancers?

Soyoun Rachel Kim

e17122

Effect of postoperative adjuvant treatment in the therapeutic management of stage I, morcellated uterine leiomyosarcoma: A Korean multicenter study.

Se Ik Kim

e17106

Effects of nivolumab alone or combination with molecular targeting agents for recurrent and refractory endometrial cancers with biomarker analyses.

Masashi Takano

e17124

Genomic biomarkers of recurrence in low-grade, early-stage endometrial adenocarcinoma.

Katie Lee Hwang

5588

Hysterectomy utilization among newly diagnosed endometrial cancer patients by body mass index category: A real-world analysis using a claims and electronic health record database.

Debra E. Irwin

e17112

Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer.

Katherine Cynthia Fuh

5590

Impact of non-compliance with guidelines in early type 1 endometrial cancers management, study from FRANCOGYN group.

Hélène Costaz

5587

Incidence of comorbidities on death certificate data in women with gynecological cancers.

Mary Elizabeth McLaughlin

e17127

Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients?

Sahin Lacin

e17107

Is uterine cancer screening indicated or possible in high risk special populations?

Susan Lee

e17126

Lynch-like syndrome in endometrial cancer: Features of a growing population.

Sushmita Gordhandas

5585

Mismatch repair deficiency as a predictor of adjuvant radiotherapy response in endometrioid endometrial carcinoma.

Stefan Kommoss

5586

Mutational landscape of endometrial cancer identified by prospective clinical sequencing in a nationwide cancer network.

Julian C. Schink

e17123

NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.

Helen Mackay

TPS5609

Patterns of distant metastases in patients with endometrial carcinoma: A SEER population-based analysis.

Jun Li

e17109

Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).

Panagiotis A. Konstantinopoulos

5502

Quality of care and survival of women with uterine cancer by Hispanic origin: An NCDB analysis.

Charlotte Gamble

e17120

Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.

Gerardo Colon-Otero

5510

Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.

Gloria S. Huang

5509

Sonographic and histopathologic characteristics of MMR-deficient endometrial cancer.

Daniel Arnold Smith

e17111

The incidence of microscopic adnexal metastatic disease in women with presumed early stage endometrial cancer.

Wafa Khadraoui

e17128

The prognostic significance of white adipose tissue inflammation in advanced-stage, high-grade, and serous endometrial cancers.

Vance Broach

5589

Transcriptomic characterization of endometrial cancer in order to find new therapeutic targets.

Monica Parra-Grande

e17113

Trends of endometrial cancer incidence from 2000 to 2015 in the United States.

V V Pavan Kedar Mukthinuthalapati

5591

Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?

Ryan Kahn

e17119